Pharma Focus Europe

Numab Therapeutics and Ono Pharmaceutical Co., Ltd. Announce Collaboration Agreement for the Development of Multispecific Antibody NM49 in Cancer Treatment

Thursday, February 15, 2024

Numab Therapeutics AG ("Numab") and Ono Pharmaceutical Co., Ltd. ("Ono Pharmaceutical") have jointly announced a collaboration to globally research, develop, and commercialize NM49, a multispecific antibody engineered to stimulate the phagocytosis of tumor-associated macrophages. NM49 was identified through Numab's proprietary discovery and engineering technology platform.

As per the agreement, Ono Pharmaceutical has the option to in-license NM49 from Numab for global development and commercialization, while Numab retains the option to co-develop and commercialize NM49 in the United States. This option can be exercised prior to the initiation of Phase III clinical trials. If exercised, Numab will participate in co-promotion and share profits equally in the United States. Numab will manage preclinical studies and CMC activities, with Ono Pharmaceutical covering related costs. If the program progresses to clinical development, Ono Pharmaceutical will cover development and associated costs. Numab will receive an undisclosed upfront payment and may be entitled to additional payments contingent upon achieving specific development, regulatory, and sales milestones, along with tiered royalties on net sales.

Numab, expressed excitement about the collaboration, noting it as the third partnership with Ono Pharmaceutical. He highlighted that this collaboration is the first instance where Numab has the option to co-develop and commercialize in the United States, which would expand Numab's product pipeline and enhance research and development productivity.

Ono Pharmaceutical, emphasized the strengthening of their partnership with Numab. He stressed their commitment to leveraging Numab's multispecific antibody platform in the development and commercialization of NM49, aiming to swiftly bring it to patients as a new treatment option.

 

Source: globenewswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva